The inhibition process of HIV-1 integrase by diketoacids molecules: Understanding the factors governing the better efficiency of dolutegravir
- 1 July 2017
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 488 (3) , 433-438
Abstract
No abstract availableKeywords
Funding Information
- Research Council of Saint-Joseph University of Beirut, Lebanon (FS71)
- Lebanese National Council for Scientific Research (FS80)
- French Institute- Lebanon
- French-Lebanese Program CEDRE (35327UJ)
This publication has 35 references indexed in Scilit:
- Structural biology of retroviral DNA integrationVirology, 2011
- Resistance to Integrase InhibitorsViruses, 2010
- HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimensJournal of Antimicrobial Chemotherapy, 2010
- Retroviral intasome assembly and inhibition of DNA strand transferNature, 2010
- Integrase inhibitors in salvage therapy regimens for HIV-1 infectionCurrent Opinion in HIV and AIDS, 2009
- Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialThe Lancet, 2007
- Human Immunodeficiency Virus Type 1 Assembly, Release, and Maturation2007
- Novel HIV-1 Integrase Inhibitors Derived from Quinolone AntibioticsJournal of Medicinal Chemistry, 2006
- Integrase inhibitors to treat HIV/AidsNature Reviews Drug Discovery, 2005
- Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymesProceedings of the National Academy of Sciences, 2002